Myomo (MYO) Stock Price, News & Analysis

Company Overview

Myomo, Inc. (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America. The company provides training, fitting and ongoing support to clinicians and patients, while also securing reimbursement agreements with Medicare and private insurers. In addition to its core device offering, Myomo continues to invest in software enhancements and data analytics to improve patient outcomes and support clinician decision-making.

Founded in 2002 and headquartered in Cambridge, Massachusetts, Myomo emerged from research conducted at the Massachusetts Institute of Technology. Since its inception, the company has focused on translating advanced robotics technology into practical medical solutions. Myomo completed its initial public offering in 2014, enabling expanded clinical trials and commercialization efforts.

Looking ahead, Myomo is pursuing next-generation wearable orthoses that aim to reduce device weight, enhance battery life and broaden indications to other parts of the body. The company’s ongoing research and development efforts remain centered on improving quality of life for patients with neuromuscular impairments and advancing the field of medical robotics.

Key Stats

• Today's Range: $0.84 to $0.88
• 50-Day Range: $0.84 to $2.21
• 52-Week Range: $0.81 to $7.17
• Volume: 2.11 million shs
• Average Volume: 726,141 shs
• Market Capitalization: $32.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.17
• Consensus Rating: Buy

Myomo Stock Analysis - MarketRank™

Myomo scored higher than 72% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Myomo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Myomo has a consensus price target of $8.17, representing about 858.5% upside from its current price of $0.85.

Amount of Analyst Coverage

Myomo has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Myomo are expected to grow in the coming year, from ($0.18) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Myomo is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Myomo is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Myomo has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.20% of the float of Myomo has been sold short.

Short Interest Ratio / Days to Cover

Myomo has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Myomo has recently decreased by 23.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Myomo does not currently pay a dividend.

Dividend Growth

Myomo does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.20% of the float of Myomo has been sold short.

Short Interest Ratio / Days to Cover

Myomo has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Myomo has recently decreased by 23.68%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Myomo has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Myomo this week, compared to 2 articles on an average week.

Search Interest

9 people have searched for MYO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added Myomo to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Myomo insiders have bought more of their company's stock than they have sold. Specifically, they have bought $160,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 4.54% of the stock of Myomo is held by insiders.

Percentage Held by Institutions

44.99% of the stock of Myomo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MYO Stock Analysis - Frequently Asked Questions

How have MYO shares performed this year?

Myomo's stock was trading at $6.03 at the start of the year. Since then, MYO stock has decreased by 85.9% and is now trading at $0.8520.

How were Myomo's earnings last quarter?

Myomo, Inc. (NYSEAMERICAN:MYO) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.01. The company had revenue of $9.21 million for the quarter, compared to the consensus estimate of $7.95 million. Myomo had a negative trailing twelve-month return on equity of 50.87% and a negative net margin of 22.87%.
Read the conference call transcript.

Who are Myomo's major shareholders?

Top institutional shareholders of Myomo include Rosalind Advisors Inc. (9.51%), AIGH Capital Management LLC (9.88%), Journey Advisory Group LLC (2.43%) and Geode Capital Management LLC (1.86%). Insiders that own company stock include Paul R Gudonis, Thomas F Kirk, David A Henry, Micah Mitchell, Harry Kovelman, Milton Mayo Morris and Thomas Aloysius Jr Crowley.
View institutional ownership trends.

How do I buy shares of Myomo?

Shares of MYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Myomo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Myomo investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Jabil (JBL), Novo Nordisk A/S (NVO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 9/15/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSEAMERICAN:MYO
• CIK: 1369290
• Web: myomo.com
• Phone: (617) 996-9058
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Myomo: $8.17
• High Price Target: $11.50
• Low Price Target: $5.00
• Potential Upside/Downside: +851.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.18 million
• Net Margins: -22.87%
• Pretax Margin: -21.76%
• Return on Equity: -50.87%
• Return on Assets: -27.00%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 2.39
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $32.55 million
• Price / Sales: 1.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.82 per share
• Price / Book: 1.05

Miscellaneous

• Outstanding Shares: 37,800,000
• Free Float: 36,085,000
• Market Cap: $32.43 million
• Optionable: Not Optionable
• Beta: 1.43